

# Yorkshire and Humber Neonatal Operational Delivery Network Clinical Guideline

***PAN***

## Hyperkalaemia

**Author &/Or Working Group  
Name**

**Dr Anjana Adonchiyalage**

**Date Written/Reviewed**

**Written 2018, most recent update Feb  
2024**

**Date Ratified**

**March 2024**

**Next Review due Date**

**March 2029**

This clinical guideline has been developed to ensure appropriate evidence based standards of care throughout the Yorkshire and Humber Neonatal Operational Delivery Network. The appropriate use and interpretation of this guideline in providing clinical care remains the responsibility of the individual clinician. If there is any doubt discuss with a senior colleague.

# Contents Page

Section	Topic	Page Number
<b>A</b>	<b>Guideline Summary</b>	*
1.	Aims	3
2.	Flow Chart/Summary Page of Recommendations	4
<b>B</b>	<b>Full Guideline &amp; Evidence</b>	<b>5</b>
1.	Background	5
2.	Aim	5
3.	Areas Outside of Remit	5
4.	Evidence	
	4.1 Definition of hyperkalaemia	5
	4.2 Cardiac arrhythmias	6
	4.3 Emergency treatment if risk of arrhythmia	6
	4.4 Causes of hyperkalaemia	6
	4.5 Investigations	7
	4.6 Other aspects of management	7
	4.7 Hyperkalaemic cardiac arrest in the neonatal unit	7
	4.8 Drug treatment of hyperkalaemia	8
	4.9 Flow chart for administration of insulin and glucose	10
5.	Education Resources	10
6.	Audit Criteria	10
7.	References	11
8.	Appendices	
	Appendix 1 Unit specific example: Drugs for the management of hyperkalaemia in the neonate	12
	Appendix 2 Guide for salbutamol inhalation	13
	Appendix 3 ECG changes with high and low potassium	16
9.	Version Control	17

## **A Guideline Summary**

### **1. Aims**

To provide evidence-based management of hyperkalaemia in neonates

### **2. Flow Chart/Summary Page of Recommendations**

## Stepwise Approach to Management of Hyperkalaemia

**Assumed K<sup>+</sup> > 6.5 mmol/L**

**Confirm true K<sup>+</sup> level with urgent venous/arterial sample**

Stop all K<sup>+</sup> retaining drugs, avoid the use of suxamethonium and stop all K<sup>+</sup> containing fluids, review nephrotoxic drugs

**Assess for risk of arrhythmia**

ECG changes\*

Rapid rise of K<sup>+</sup> to >7.5 mmol/L

Acidosis

Known hypocalcaemia or hypomagnesaemia

Oliguria

Acute renal failure

Cardiac disease

**True K<sup>+</sup> > 6.5 mmol/L (sick baby)**

**OR**

**K<sup>+</sup> >6.5 mmol/L and rising on 2 sequential measurements  
(well premature baby)**

**Escalate the level of care, monitor closely with continuous ECG & inform on-call consultant**

**If significant risk of arrhythmia stabilise myocardium**

**10% Calcium gluconate 0.5 ml/kg IV OR Calcium Chloride 0.125mmol/Kg  
(Repeat after 5min if ECG changes persists)**

**Correct Hyperkalaemia**

**Stop milk feeds and other exogenous sources of K<sup>+</sup>**

**First Line**

Salbutamol (IV) bolus 4 micrograms/kg (can repeat after 2 hours)  
OR

Inhaled/Nebulised Salbutamol 2.5-5mg (can repeat as needed)  
OR

Glucose 20% 2.5 – 5 ml/kg/hour AND Insulin 0.1 - 0.6 units/kg/hour to keep blood  
Glucose 4-7mmol/L (start Insulin at 0.1 units/kg/hr and titrate)

**Consider combining Salbutamol (IV or Nebulised) with IV  
Glucose + Insulin in severe or resistant hyperkalaemia cases**

Consider correction of acidosis if pH < 7.2 and BE < -10mmol/L or  
HCO<sub>3</sub> < 16mmol/L

Sodium bicarbonate 1- 2 mmol/kg (8.4% if poor urine output)  
(Do not give Sodium bicarbonate if Corrected Ca < 2 or Ionised Ca < 1, Correct low  
Ca before correcting Acidosis)

**Second Line**

Furosemide (iv) 1mg/kg

**Persistent hyperkalaemia**

Salbutamol infusion 0.3– 1 micrograms/kg/min

**CONSIDER**

Regular Furosemide +/- Calcium resonium or Dialysis or exchange transfusion

**Other Investigations**

Urea and electrolytes –  
(baseline and 4 hourly)

Calcium  
Magnesium  
Chloride  
Bicarbonate  
Glucose

**\*ECG changes:**

Serum K<sup>+</sup> 6.5-8mmol/L  
peaked T waves,  
prolonged PR interval,  
reduced p waves,  
widening QRS interval,  
amplified R wave  
Serum K<sup>+</sup> >8mmol/L  
absent P waves, bundle  
branch block, widening  
QRS, eventual  
VF/asystole

Refer to the table on page 6 and appendices for more details on medication doses & administration

## **B Full Guideline & Evidence**

### **1. Background**

Neonates with hyperkalaemia require close monitoring. Normal levels of serum potassium may differ depending on the gestation and condition of the infant.

Reversible hyperkalaemia in neonates was first recognised in 1959. It is defined as serum potassium above 6.5mmol/l.<sup>1,2</sup>

True hyperkalaemia is a medical emergency due to the effect on cardiac myocyte function which can result in cardiac arrhythmias and possible death<sup>3</sup>. Prompt treatment is necessary.

### **2. Aim**

To provide evidence-based management and recommendations for defining, monitoring and treating hyperkalaemia in neonatal patients.

### **3. Areas Outside of Remit**

Management requiring specialist renal input for rare inherited conditions.

### **4. Hyperkalaemia**

#### **4.1 Definition of Hyperkalaemia**

The normal range for potassium levels is 3.5-6.0 mmol/L. Gas samples that are normal are reassuring and results should be used.

Where a level between 6.0-6.5mmol/L is identified a repeat gas sample should be obtained. Patients should be regularly monitored to ensure the level is not increasing and consideration should be given to reducing additional sources of potassium e.g. in iv fluids/PN.

#### Hyperkalaemia $K^+ \geq 6.5\text{mmol/L}$

A raised  $K^+$  level on capillary sampling is commonly due to haemolysis; however, poor flowing venous samples may be as unreliable.

When interpreting a result, take the clinical state of the infant into consideration. If the baby is greater than 1kg, more than 1 week old, has good renal function, and is relatively well a routine sample can be repeated.

In all other cases, a more urgent sample should be sent (free flowing arterial or venous), with immediate simultaneous blood gas machine analysis to give an instant guide.

If the baby is unwell, or two capillary samples have already been sent, further samples should be free-flowing venous or arterial blood.

When hyperkalaemia is identified and suspected to be true: Stop all potassium retaining drugs, avoid the use of suxamethonium and stop all exogenous sources of potassium early.

#### Unwell babies:

Where acute renal failure is known or possible, a single true  $K^+ > 6.5\text{mmol/L}$  should be monitored closely. Repeat a venous sample after 2-3 hours.

#### Well babies:

Premature infants in particular, may develop hyperkalaemia without significant renal impairment (non-oliguric hyperkalaemia of prematurity). This requires monitoring but may not need treatment. Repeat sample after 4 hours. Two sequential measurements of  $K^+ \geq 7.0\text{mmol/L}$ , and rising, require treatment.

### **4.2. Cardiac Arrhythmias**

Arrhythmias are unlikely unless  $K^+ > 7.5\text{ mmol/L}$  with ECG changes best confirmed on formal ECG. Be aware of ECG artefacts as they are common in neonatal ECGs and it is recommended to manually calculate intervals as computerised calculations are often inaccurate in neonates.<sup>21</sup> Early changes include peaked T waves, prolonged PR interval and widened QRS and are due to decreased conduction velocity. Continued rises in  $K^+$  levels may lead to ventricular tachycardia or sinus bradycardia and in severe cases ventricular fibrillation and asystole.<sup>3,4</sup>

### **4.3. Emergency Treatment if risk of arrhythmia**

To control cardiac excitability, give:

calcium gluconate 10% (IV) 0.5 ml/kg (0.11 mmol/kg) (Alternative higher dose 2ml/kg (0.46mmol/kg))

or

calcium chloride 0.125mmol/kg<sup>5,6</sup> (Alternative higher dose 0.5mmol/kg)

Onset is within 5 minutes. Can repeat dose after 5 minutes if ECG changes persists.

Check concentrations available in the ward when calculating dose and give ideally via a central line (in an emergency can give peripherally with caution). Do not administer calcium simultaneously with sodium bicarbonate or with parenteral nutrition through the same venous access, use a separate access.

Hyperkalaemia inactivates sodium channels and increases membrane excitability by reducing the membrane resting potential. Calcium antagonises the effects of hyperkalaemia on the cardiac myocyte returning the resting potential to near normal. It is cardio-protective but does not reduce potassium serum levels.

**Aim to keep the ionised calcium levels (on the blood gas)  $> 1.0$ .**

### **4.4 Causes of Hyperkalaemia**

The cause must be considered and in general, appropriate management will reduce the potassium level. Hyperkalaemia can result from:

- a. Increased  $K^+$  intake
- b. Decreased  $K^+$  excretion
- c. Shift of  $K^+$  from the intracellular to extracellular space in the immature erythrocyte. (Non-oliguric hyperkalaemia of prematurity without significant renal impairment)<sup>8</sup>.

Other causes of neonatal hyperkalaemia are relatively rare and may be seen in the following conditions:

- Oliguric acute renal failure due to potassium retention.
- Shock with tissue damage causing potassium leakage from the intracellular space - some potassium will be redistributed to the intracellular space if acidosis is corrected (see below).
- Unexplained in the acute phase of respiratory distress syndrome - incidence may be reduced if mother receives antenatal steroids.<sup>9</sup>
- Hypoaldosteronism, pseudohypoaldosteronism and hypoadrenalism (with hyponatraemia) - rare.
- Drug induced due to potassium retention (spironolactone, potassium supplements) or release from cells (suxamethonium).
- Accidental overdose in intravenous fluids. If this is considered retain IV fluids once stopped for analysis in pharmacy.

#### 4.5. Investigations

When commencing treatment for hyperkalaemia the following may aid identification of the cause and set a baseline for treatment:

- Urea and electrolytes - repeat 4 hourly until serum potassium has stabilised
- Calcium, magnesium, chloride, bicarbonate, glucose and urine analysis.

#### 4.6. Other aspects of Management

- Recheck serum potassium levels after each intervention or at least every 4 hours until normal levels are stabilised.
- Watch for fluid overload in the presence of renal failure and adjust fluid intake accordingly.
- Monitor blood glucose hourly if treating with glucose and insulin.
- In severe hyperkalaemia of unknown cause, or if there is a high suspicion of adrenal insufficiency/low cortisol (with associated Acidosis, low sodium, low Glucose), IV hydrocortisone can be considered (Stat dose of IV Hydrocortisone 4mg/kg)

#### 4.7. Hyperkalaemic Cardiac arrest in Neonatal unit

Hyperkalaemia is a well known cause of both pulseless ventricular tachycardia (VT) and ventricular fibrillation (VF) both of which are shockable cardiac arrest rhythms. If prompt actions are not taken to do rhythm check and defibrillation these rhythms can degenerate quickly to asystole.

Most neonatal unit staff are more familiar with the NLS resuscitation algorithm and tend to stick with the same for most of out of the delivery room neonatal cardiac arrests which is acceptable as most of other out of delivery room neonatal cardiac arrests are hypoxic or ischemic and non-shockable.

However, in the face of known hyperkalaemic cardiac arrests in neonatal patients, it is essential to consider the possibility of patients being in shockable rhythm and consider following the APLS cardiac arrest algorithm rather than following the NLS resuscitation algorithm which does not include cardiac rhythm check or defibrillation.


#### 4.8 Drug Treatment of Hyperkalaemia (see additional information Appendix 1 and 2)

	Drug	Mechanism of Action
Prevention Of Arrhythmias	<p><b>Calcium Gluconate 10% (iv) 0.5ml/kg (0.11 mmol/kg)</b> slow injection over 5-10 minutes (Alternative higher dose 2ml/kg (0.46mmol/kg))</p> <p>Or</p> <p><b>Calcium Chloride 0.125 mmol/kg</b> iv infusion over 15 minutes (Alternative higher dose 0.5mmol/kg)</p> <p><b>NB: Check concentrations available in the unit when calculating the dose. Ideally give via central venous route. Give via separate intravenous line from sodium bicarbonate and parenteral nutrition, if needs administering them simultaneously.</b></p>	<p><b>To stabilise myocardium. Used if K+ &gt;7.5 or ECG is abnormal</b></p> <p><b>Onset of action within 5 minutes. Can repeat dose after 5 minutes if ECG changes persist (Caution in repeating doses if used higher dose)</b></p>
1 <sup>st</sup> Line	<p><b>Salbutamol bolus</b> (IV) 4 micrograms/kg bolus over 5 - 10 minutes - may be repeated after 2 hours<sup>2</sup></p> <p><b>OR</b></p> <p><b>Inhaled/Nebulised Salbutamol 2.5 – 5 mg<sup>6</sup> (Alternative lower dose in Australasian guidelines is 400micrograms/kg)</b> can repeat as needed. (If readily available, consider in patients with no IV access, while establishing IV access or while preparation of IV medications)</p> <p><b>OR</b></p> <p><b>Insulin</b> 0.1 - 0.6 units/kg/hour <b>AND Glucose</b> (Dextrose) 20% 2.5 - 5 ml/kg/hour (equivalent to glucose 0.5 - 1 g/kg/hr) via central line OR Glucose 10% 5-10ml/kg/hr peripherally if no central access available.</p> <p>Start Insulin at 0.1 units/kg/hour (Can use your own unit insulin regimen if available and preferred). Target blood glucose level to be maintained at the range of 4-7 mmol/L.</p> <p>It may be appropriate to include the Glucose within the maintenance fluids if being given peripherally or if there are concerns regarding fluid balance/overload. Consider higher concentration (Up to Glucose 30%)<sup>7</sup> in fluid restricted patients with central venous access.</p> <p><b>NB: Glucose infusions and insulin infusions should always be run through the same intravenous line (central or peripheral) to ensure both infusions stop if the IV line blocks or leaks.</b></p> <p><b>Close monitoring is required (see flow chart below)</b></p>	<p>Both Salbutamol and Glucose + Insulin reduce plasma K<sup>+</sup> by redistribution to intracellular space</p> <p>Onset of action: Salbutamol within 5 minutes Glucose + Insulin within 15 minutes</p> <p>Evidence suggest equal efficacy of Salbutamol and Glucose + Insulin in lowering of plasma K<sup>+</sup> and Combining Salbutamol (IV or Nebulised) with IV Glucose + Insulin is more effective than monotherapy and should be considered in more severe and resistant cases <sup>8,12,13,14</sup> Salbutamol has a benefit of maintaining stable blood Glucose levels comparing to Glucose + Insulin therapy <sup>22</sup> Recommend to consider patient factors (Renal function/ Fluid restriction/ availability &amp; type of vascular access / type of airway support) and Unit factors (Availability of medications/ devices/</p>



		trained staff) in selection of 1 <sup>st</sup> line medication.
<b>2<sup>nd</sup> Line</b>	<b>Furosemide (iv)</b> 1 mg/kg slow injection over 5-10 minutes.	Increased renal excretion of K <sup>+</sup> ion by reduced re-absorption in Loop of Henle <sup>3</sup> . Less effective if renal impairment present.
<b>Persistent hyperkalaemia</b>	<p><b>Salbutamol infusion</b> 0.3 – 1 microgram/kg/min (watch for fluid overload in renal failure) To be given after second salbutamol bolus</p> <p><b>+/-</b></p> <p>Regular Furosemide</p> <p><b>CONSIDER</b></p> <p><b>For Term Neonates: Calcium Resonium</b> (rectally): 125 - 250 mg/kg 3-4 times per day - exclude if any risk of GI tract pathology<sup>8,10,11</sup> (Suspend powder in 5ml of water or 10% Glucose per 1 g calcium resonium given. Irrigate the colon 6 - 12 hours after with a gentle saline lavage) <b>NB</b> Ineffective and dangerous in preterm infants for treatment of non-oliguric hyperkalaemia.<sup>12</sup></p> <p><b>Dialysis or exchange transfusion</b> - discuss with Consultant Neonatologist and Paediatric Nephrologists. There is limited evidence to support exchange transfusion.</p>	Removal of K <sup>+</sup> by cation exchange
<b>Acidosis pH &lt;7.2 and BE &lt; - 10 mmol/L</b>	<p><b>Sodium bicarbonate (IV)</b> 1 - 2 mmol/kg (2-4 ml/kg 4.2% solution or 1-2 ml/kg 8.4% solution) over 20-30 minutes.</p> <p>Monitor for hypernatraemia and fluid overload</p> <p>Do not give Sodium bicarbonate if Corrected Ca&lt;2 or Ionised Ca&lt;1. Sodium bicarbonate will further reduce plasma Ca and destabilise myocardium.</p>	<p>Onset of action 1 hour</p> <p>Reduction of plasma K<sup>+</sup> by redistribution to intracellular space<sup>3</sup></p>

## 4.9 Flow chart for Administration of Glucose and Insulin



**NB. If Blood glucose < 2, stop insulin until glucose delivery increased and blood glucose above 4 mmol/L**

It may be appropriate to include the Glucose within the maintenance fluids if being given peripherally (due to larger volume) or if there are concerns regarding fluid balance/overload.

If there are difficulties in maintaining blood glucose levels with increasing rates of Glucose 20% consideration should be given to increasing the Glucose concentration further (Can go up to 30%. Concentrations >12.5% should only be administered via central route). Discuss with consultant.

Can use your own unit Insulin/Glucose regimen if available and preferred.

### 5. Education Resources

### 6. Audit Criteria

Management following the guideline with levels done at appropriate time.

## 7. References

The guideline has been adapted from the Hull & East Yorkshire, Leeds Teaching Hospital and Jessop Wing hyperkalaemia guidelines. Thank you to all those who have contributed.

1. Mildenberger E. & Versmold HT. 2002. Pathogenesis and therapy of non-oliguric hyperkalaemia of the premature infant. *European Journal of Pediatrics* 161: 415–422)
2. Vemgal P et al. Cochrane database of systematic reviews 2009. Interventions for non-oliguric hyperkalaemia in preterm neonates (review)
3. Masilamani K & Van der Voort J. 2012. The Management of acute Hyperkalaemia in neonates and children. *Archives of Disease in Childhood* 97 376-380
4. Usher R. 1959. The Respiratory Distress Syndrome of Prematurity. Changes in Potassium in the Serum and the Electrocardiogram and Effects of Therapy. *Pediatrics* 24 562
5. Neonatal Formulary 5th Edition 2008. BMJ Books. [www.neonatalformulary.com](http://www.neonatalformulary.com)
6. Children's BNF 2019-2020. BMJ Publishing Group. Royal Pharmaceutical Society of Great Britain and RCPCH Publications.
7. Guidance for prescribing and administration of Parenteral Nutrition on Paediatric Intensive Care. <http://www.leedsformulary.nhs.uk> .Accessed on May 2020
8. Mahony BA. Cochrane database of systematic reviews 2005 Apr. Emergency interventions for Hyperkalaemia
9. Uga N. *Pediatr Int.* Dec 2003;45(6):656-60. Antenatal steroid treatment prevents severe hyperkalaemia in very low birth weight infants.
10. Haycock GB. Management of acute and chronic renal failure in the newborn. *Seminars in neonatology* Aug 03; 8:325 – 334.
11. Grammatikopoulou T. *Acta Paediatr* 2003;92(1):118-20. Benefits and risks of calcium resonium therapy in hyperkalaemic preterm infants.
12. O'Hare F & Molloy E. 2008. What is the best treatment for hyperkalaemia in the preterm infant? BestBets- Best Evidence Topics as accessed on trip database Sept 2016 <http://www.bestbets.org/bets/bet.php?id=01571>
13. Hu PS, Su BH, Peng CT & Tsai CH. 1999. Glucose and insulin infusion versus kayexalate for the early treatment of non-oliguric hyperkalemia in very-low-birth-weight infants. *Acta Paediatrics Taiwan* 40 314–318
14. Malone TA. 1991. Glucose and insulin versus cation-exchange resin for the treatment of hyperkalemia in very low birth weight infants. *Journal of Pediatrics* 118 121–123
15. British National Formulary for Children. NICE 2016
16. Guy's and St Thomas's paediatric formulary 2012
17. Management of hyperkalaemia in children. EMEESY Children's Kidney Network guidelines. <https://www.emeesykidney.nhs.uk/> Accessed on January 2020.
18. NW Newborn drug protocol – salbutamol administration. <http://www.adhb.govt.nz/newborn/DrugProtocols/SalbutamolAdministration.htm> Accessed on May 2020
19. Neonatal Medication protocol – Kings Edward Memorial Hospital. <https://www.wnhs.health.wa.gov.au/> Accessed on May 2020
20. Babylog VN800/ VN600 – Draeger. [https://www.draeger.com/Library/Content/9055638\\_04\\_IfU\\_Babylog\\_VN800\\_600\\_SW1\\_n\\_en.pdf](https://www.draeger.com/Library/Content/9055638_04_IfU_Babylog_VN800_600_SW1_n_en.pdf) Accessed on July 2020
21. Schwartz PJ, Garson Jr A, Paul T, Stramba-Badiale M, Vetter VL, Villain E, Wren C. Guidelines for the interpretation of the neonatal electrocardiogram. *European heart journal.* 2002 Sep 1;23(17):1329-44.

22. Rocha G. Inhaled Pharmacotherapy for Neonates: A Narrative Review. *Turk Arch Pediatr.* 2022 Jan;57(1):5-17.
23. PainH8er, 26 Dec 2017, Albuterol Administration To An Intubated Patient. <https://youtu.be/FerArhaX2Z8?si=O0vxBnAueWbG2ZJq>
24. Sean Scott, 4 Oct 2013, Salbutamol MDI for ETT – MacGyver Style. [https://youtu.be/ZM0FMUcddA?si=95eUMugl2Nv4M8\\_P](https://youtu.be/ZM0FMUcddA?si=95eUMugl2Nv4M8_P)
25. AerogenLtd, 28 Apr 2020, Aerogen set up for Mechanical Ventilation. <https://youtu.be/cR-cA3uhXo?si=2RSPWa6tV6A1KNfR>
26. AerogenLtd, 19 Oct 2017, Aerogen Solo en el conector en Y. [https://youtu.be/m-kj8\\_VkgOU?si=9O3YZnN6CZ8fLvzr](https://youtu.be/m-kj8_VkgOU?si=9O3YZnN6CZ8fLvzr)
27. Life with a Vent, 27 Feb 2022, How to connect a nebulizer to a ventilator. <https://youtu.be/Z5Lx--xlj28?si=MPK8H4loKaGhYhOs>
28. Teymouri N, Mesbah S, Navabian SMH, et al. ECG frequency changes in potassium disorders: a narrative review. *Am J Cardiovasc Dis.* 2022;12(3):112-124. Published 2022 Jun 15.

## 7. Appendices

**Appendix 1 Unit specific example: Drugs for the management of hyperkalaemia in the neonate**

**Appendix 2 Guide for Salbutamol inhalation (proposed guide, use local unit guide if available and preferred)**

**Appendix 3 ECG Changes in high & low serum Potassium<sup>28</sup>**

**Appendix 1 Unit specific example: Drugs for the management of hyperkalaemia in the neonate**

Drug	Stock on NICU	Dilution	Administration
Calcium Gluconate	Solution for injection 10%, 225 micromol/ml	Used undiluted in emergency (Central) For peripheral administration dilute X 5 volumes with Glucose 5% or Sodium chloride 0.9%.	Infuse over 5- 10 minutes (Preferred via central route, needs cautions to avoid extravasation)
Calcium Chloride	Solution for injection 10% (0.7mmol Ca in 1ml) 14.7% (1mmol Ca in 1ml)	Dilute with Sodium chloride 0.9%	Infuse over 15 minutes (Only via central route, needs cautions to avoid extravasation)
Salbutamol IV	Solution for injection 500 microgram/ml	Dilute with Water for Injection, 0.9% Sodium chloride, Glucose 5% solution.  1. Take 1 ml of the 500 micrograms/ml solution and dilute <b>to</b> a total volume of 25 mls → this gives a 20 microgram/ml solution	For salbutamol bolus: 4 microgram/kg = 1 ml/kg of final solution; give over 5-10 minutes  For salbutamol infusion the 4 microgram/ml can be used as well. In fluid restricted patients higher concentrations (e.g. 20 microgram/ml) can be used. If necessary, neat solution can be given, <i>via central line only</i> .

		2. Take 1 ml of this 20 microgram/ml solution and dilute <b>to</b> a total volume of 5 mls → this gives a 4 microgram/ml solution (= final solution)	
Salbutamol Inhalation	Please refer to appendix 2 below		
Insulin	Humulin S (Soluble insulin) 100 units/ml Actrapid (Soluble insulin) 100 units/ml	Add 10 units of Humulin S/ Actrapid to 50 mls of 5% dextrose → 0.2 unit per ml	Using this solution 0.1-0.6 unit/kg/hour corresponds with 0.5 - 3 ml/kg/hour
		This is a suggestion to consider only. Can follow individual unit's Insulin administration guide if available and preferred.	
Glucose (Dextrose) 20% (may be available as stock solution)	Dextrose 50% Dextrose 10%	Remove 125 mls from bag of 10% dextrose. Add 125 mls of dextrose 50% to make an overall concentration of 20% dextrose	Run this solution at 2.5 – 5 mls/kg/hr via a central line. Run dextrose solution and insulin on the same IV line.
Furosemide	Furosemide solution for injection 10mg/ml	Dilute with Sodium chloride 0.9%	Infuse over 5-10 minutes
Sodium bicarbonate	Solution for injection 8.4%, 10 ml amps.	8.4% sodium bicarbonate solution can be used neat if given slowly and <i>via central line only</i> .  It is preferably diluted to 4.2% with 5 or 10% Dextrose, or 0.9% Sodium chloride (not in renal patients).	Infusion over 20-30 minutes. Ideally be given centrally, if given peripherally (≤4.2%) needs extra cautions (Should not administer simultaneously with Calcium or Parenteral nutrition through the same line)
Calcium resonium	Calcium resonium powder for Oral/Rectal Suspension	Mix each 1g of resin with 5 ml of water or 10% glucose  (Familiarise with the local hospital products. Contact your pharmacist)	For rectal use only The dose should be retained as long as possible, up to 12 hours The colon should be irrigated with 1-2 mls of 0.9% sodium chloride before a new dose is inserted or 12 hours after

**Appendix 2: Guide for Salbutamol inhalation (proposed guide, use local unit guide if available and preferred)**

In neonates preferred route of administration of Salbutamol is intravenous. But inhalation/nebulisation route can be useful in certain circumstances as hyperkalaemia is a medical emergency.

**Consider Inhaled/nebulised salbutamol for:** patients with no IV access or limited IV access, fluid restricted patients.

**Drug preparation:** Salbutamol nebuliser liquid 2.5mg/2.5ml or 5mg/2.5ml or Salbutamol Metered dose inhaler 100micrograms per puff

**Dose:** 2.5 – 5 mg (BNFC recommended dose) (the alternative lower dose recommended in Australasian guidelines is 400 micrograms/Kg/dose<sup>18,19</sup>)

**Dilution:** For Nebulization dilute with 0.9% Sodium Chloride solution or can use Neat solution

**Administration (for patients on minimal or no respiratory support):**

- Use standard nebulisation device with correct size mask.
- Needs cautions to keep nebuliser liquid chamber upright to avoid spilling of liquid (may need to elevate head end of patient).
- Needs gas flow of 4-6 L/min to generate aerosols if use wall Oxygen/Air with the jet nebuliser. In preterm neonates use air instead of Oxygen to avoid hyperoxia.


**Administration (for intubated and ventilated patients)<sup>20, 23, 24, 25, 26,27:</sup>**

Consider the intravenous route of administration of Salbutamol as the first option. If Salbutamol inhalation is chosen, **strongly recommend to familiarise and adhere with the user guide of your own unit ventilator specific inhalation technique.** As hyperkalaemia is an emergency, the staff should be trained enough to assemble equipment and start inhalation very quickly if this method of administration is chosen. Following steps are only a general guide and may vary depending on the type of ventilator.

- Inhaled Salbutamol can be administered to an intubated patient using either using metered dose inhaler device or nebulization technique.
- If using metered dose inhaler – use the salbutamol canister with 50ml BD plastic syringe and connecting port to the breathing circuit (MacGyver Technique – Please see the video links or Embrace guidance). May need to manually bag while administering inhaler. (MacGyver Technique - <https://youtu.be/FerArhaX2Z8?si=O0vxBnAueWbG2ZJq> [https://youtu.be/ZM0FMUcddA?si=95eUMugl2Nv4M8\\_P](https://youtu.be/ZM0FMUcddA?si=95eUMugl2Nv4M8_P) )
- If using nebulization, can use either jet nebuliser (Standard) or vibrating mesh nebuliser (Aerogen) to administer salbutamol. (Using Aerogen device - <https://youtu.be/cR-cA3uhXo?si=2RSPWa6tV6A1KNfR> , [https://youtu.be/m-kj8\\_VkgOU?si=9O3YZnN6CZ8fLvzr](https://youtu.be/m-kj8_VkgOU?si=9O3YZnN6CZ8fLvzr) )
- For the nebulization the patient should be on the pressure controlled ventilation mode (Change mode if on the volume controlled mode).
- Most ventilators have nebulisation option on advanced settings under Procedures/Manoeuvres option.
- May need to remove the Neonatal flow sensor from the ventilator circuit and switch off flow sensor option before starting nebulisation.
- Nebulisation device is needed to connect to either inspiratory limb of gas circuit or between ‘Y’ connector and ET tube depending on the ventilator. (Connecting jet nebulizer to the circuit - <https://youtu.be/Z5Lx--xlj28?si=MPK8H4IoKaGhYhOs> )
- Familiarise with additional equipment needed and make sure those equipment and medication are readily available.

- Additional devices used in nebulisation can increase respiratory dead space and resistance of gas flow. Therefore, needs close monitoring of patients during nebulisation.
- **Frequency of administration:** Repeat as required (BNFC) (Australasian guidelines recommend repeat 2 hourly, maximum 12 doses<sup>18,19</sup>)

**Appendix 3: ECG Changes in high & low serum Potassium<sup>28</sup>**





## 9. Version Control Table

<b>Version Control Table - Document History</b>			
<b>Date</b> <i>(of amendment/ review)</i>	<b>Issue No.</b> ( e.g V1)	<b>Author</b> <i>(Person/s making the amendment or reviewing the Guideline)</i>	<b>Detail</b> <i>(of amendment/misc notes)</i>
Feb 2024	V3	Dr Anjana Adonchiyalage	Potassium level defined as hyperkalaemia reduced to 6.5mmol/L Section on hyperkalaemic cardiac arrest Administration of nebulised salbutamol Addition references 21 onwards